A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
K Cathcart, J Pinilla-Ibarz, T Korontsvit, J Schwartz… - Blood, 2004 - ashpublications.org
A tumor-specific, bcr-abl-derived fusion peptide vaccine can be safely administered to
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …
patients with chronic myelogenous leukemia (CML) and can elicit a bcr-abl peptide-specific …
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
J Pinilla-Ibarz, K Cathcart, T Korontsvit… - Blood, The Journal …, 2000 - ashpublications.org
Chronic myelogenous leukemia (CML) presents a unique opportunity to develop therapeutic
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …
strategies using vaccination against a truly tumor-specific antigen that is also the oncogenic …
Synthetic tumor‐specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial
N Jain, JM Reuben, H Kantarjian, C Li… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: Imatinib is the current standard frontline therapy for chronic myelogenous
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …
leukemia (CML). In the majority of patients, imatinib induces a complete cytogenetic …
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
JM Rojas, K Knight, L Wang, RE Clark - Leukemia, 2007 - nature.com
Peptides from the e14a2 BCR-ABL junction will elicit T-cell responses in vitro. Here, 19
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …
imatinib treated CML patients in first chronic phase were vaccinated with BCR-ABL peptides …
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre …
M Bocchia, S Gentili, E Abruzzese, A Fanelli, F Iuliano… - The Lancet, 2005 - thelancet.com
Background Although imatinib is the standard treatment for chronic myeloid leukaemia, not
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
all patients reach complete cytogenetic remission (CCR) and most maintain detectable …
Dendritic cell vaccination for patients with chronic myelogenous leukemia
T Takahashi, Y Tanaka, M Nieda, T Azuma, S Chiba… - Leukemia research, 2003 - Elsevier
In this pilot study, we investigated the ability of autologous dendritic cells (DCs) pulsed ex
vivo with leukemia-specific peptide to stimulate host antitumor immunity when administrated …
vivo with leukemia-specific peptide to stimulate host antitumor immunity when administrated …
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl -positive leukemia in mice
L He, H Feng, A Raymond, M Kreeger, Y Zeng… - Cancer Immunology …, 2001 - Springer
Chronic myelogenous leukemia (CML) is a clonal disorder characterized by proliferation of
cells that possess the bcr-abl fusion gene resulting in the production of one of two possible …
cells that possess the bcr-abl fusion gene resulting in the production of one of two possible …
Immunogenicity of a p210BCR-ABL Fusion Domain Candidate DNA Vaccine Targeted to Dendritic Cells by a Recombinant Adeno-associated Virus Vector in Vitro
JY Sun, RS Krouse, SJ Forman, D Senitzer, I Sniecinski… - Cancer research, 2002 - AACR
Chronic myelogenous leukemia (CML) is characterized by at (9; 22) translocation, which
results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for …
results in the expression of chimeric BCR-ABL fusion oncoproteins that are necessary for …
Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia
K Giannopoulos, A Dmoszynska, M Kowal, J Rolinski… - Leukemia, 2010 - nature.com
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen
in chronic lymphocytic leukemia (CLL). CD8+ T cells primed with the RHAMM-derived …
in chronic lymphocytic leukemia (CLL). CD8+ T cells primed with the RHAMM-derived …
Specific human cellular immunity to bcr-abl oncogene-derived peptides
M Bocchia, T Korontsvit, Q Xu, S Mackinnon, SY Yang… - 1996 - ashpublications.org
Chronic myelogenous leukemia (CML) cells are characterized by at (9; 22) translocation,
which can encode one of two chimeric P210 bcr-abl fusion proteins, comprising products of …
which can encode one of two chimeric P210 bcr-abl fusion proteins, comprising products of …